Cargando…

Immuno(T)herapy for age‐related diseases

During the last decade, the stimulation of T‐cell function by the blockage of immunosuppressive checkpoints has experienced an outstanding impact in the treatment of cancer. Development of the chimeric antigen receptor T‐cell technology has also emerged as a powerful alternative for patients sufferi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gabandé‐Rodríguez, Enrique, Pfeiffer, Matilda, Mittelbrunn, María
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832825/
https://www.ncbi.nlm.nih.gov/pubmed/36373340
http://dx.doi.org/10.15252/emmm.202216301
_version_ 1784868134110363648
author Gabandé‐Rodríguez, Enrique
Pfeiffer, Matilda
Mittelbrunn, María
author_facet Gabandé‐Rodríguez, Enrique
Pfeiffer, Matilda
Mittelbrunn, María
author_sort Gabandé‐Rodríguez, Enrique
collection PubMed
description During the last decade, the stimulation of T‐cell function by the blockage of immunosuppressive checkpoints has experienced an outstanding impact in the treatment of cancer. Development of the chimeric antigen receptor T‐cell technology has also emerged as a powerful alternative for patients suffering from oncological processes, especially those affected by hematological neoplasms. Recent evidence suggest that the use of immunotherapy could be extended to non‐oncological diseases and could be especially relevant for age‐associated disorders, opening exciting therapeutic options for a wide range of diseases of the elderly. Here we comment on the emergence of T‐cell‐based immunotherapies as feasible approaches that could revolutionize the future of GeroScience.
format Online
Article
Text
id pubmed-9832825
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-98328252023-01-12 Immuno(T)herapy for age‐related diseases Gabandé‐Rodríguez, Enrique Pfeiffer, Matilda Mittelbrunn, María EMBO Mol Med Commentary During the last decade, the stimulation of T‐cell function by the blockage of immunosuppressive checkpoints has experienced an outstanding impact in the treatment of cancer. Development of the chimeric antigen receptor T‐cell technology has also emerged as a powerful alternative for patients suffering from oncological processes, especially those affected by hematological neoplasms. Recent evidence suggest that the use of immunotherapy could be extended to non‐oncological diseases and could be especially relevant for age‐associated disorders, opening exciting therapeutic options for a wide range of diseases of the elderly. Here we comment on the emergence of T‐cell‐based immunotherapies as feasible approaches that could revolutionize the future of GeroScience. John Wiley and Sons Inc. 2022-11-14 /pmc/articles/PMC9832825/ /pubmed/36373340 http://dx.doi.org/10.15252/emmm.202216301 Text en © 2022 The Authors. Published under the terms of the CC BY 4.0 license. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Commentary
Gabandé‐Rodríguez, Enrique
Pfeiffer, Matilda
Mittelbrunn, María
Immuno(T)herapy for age‐related diseases
title Immuno(T)herapy for age‐related diseases
title_full Immuno(T)herapy for age‐related diseases
title_fullStr Immuno(T)herapy for age‐related diseases
title_full_unstemmed Immuno(T)herapy for age‐related diseases
title_short Immuno(T)herapy for age‐related diseases
title_sort immuno(t)herapy for age‐related diseases
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832825/
https://www.ncbi.nlm.nih.gov/pubmed/36373340
http://dx.doi.org/10.15252/emmm.202216301
work_keys_str_mv AT gabanderodriguezenrique immunotherapyforagerelateddiseases
AT pfeiffermatilda immunotherapyforagerelateddiseases
AT mittelbrunnmaria immunotherapyforagerelateddiseases